Navigation Links
IRIDEX Announces Second Quarter 2010 Conference Call and Release Date
Date:7/29/2010

MOUNTAIN VIEW, Calif., July 29 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its second quarter 2010 financial results after the market closes on Thursday, August 5, 2010.  In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, August 5, 2010 to discuss the results of the quarter and other business developments.

Interested parties may access the live conference call via telephone by dialing (877) 941-1466 U.S. or (480) 629-9678 (International) and quoting Conference ID 4336037, or by visiting the Company's website at www.iridex.com.  A telephone replay will be available beginning on Thursday, August 5, 2010 through Thursday, August 12, 2010 by dialing (800) 406-7325 (US) or (303) 590-3030 (International) and entering Access Code 4336037.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, an
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
2. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
3. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
4. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
6. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
7. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
8. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
9. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
10. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
11. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Grifols, a global ... , presented results from a study demonstrating that a ... Inhibitor [Human]) increased levels of the alpha 1 ... to levels that are considered within the normal range ... condition in which low levels of the alpha 1 ...
(Date:5/22/2013)... , May 22, 2013  BD (Becton, Dickinson ... global medical technology company, announced today the publication of ... fifth Sustainability Report and it continues to focus on ... "We believe the principles of shared value — ... healthcare challenges of societies — are fundamental to our ...
(Date:5/22/2013)... , May 22, 2013 Rigel Pharmaceuticals, Inc. ... advancement of three programs in development. The first program ... inhibitor, R348, being developed by Rigel as a treatment ... aimed at oncology targets and are being conducted by ... by BerGenBio AS (BerGenBio) and a ligase inhibitor under ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
... YORK, Jan. 11, 2011 Reportlinker.com announces that ... its catalogue: Advanced Drug Delivery ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery ... drug product formulations being discovered frequently. Advanced drug ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com announces ... in its catalogue: Innovative Drug ... http://www.reportlinker.com/p0359990/Innovative-Drug-Discovery-in-Emerging-Markets.html Introduction Emerging markets ... pharmaceutical industry, but it has been unclear the ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds Innovative Drug Discovery in Emerging Markets 2Reportlinker Adds Innovative Drug Discovery in Emerging Markets 3
(Date:5/22/2013)... CoCENTRIX, a leading provider of coordinated ... Services and community providers, announced today that the ... CoCENTRIX Coordinated Care Platform (CoCENTRIXccp) as ... and coordinate care within and amongst its four ... transitioning the hospitals' official records from paper-based to ...
(Date:5/22/2013)... Denver, CO (PRWEB) May 22, 2013 ... of legal discovery management services for law firms, corporations ... Cumulus Data, Inc., a cloud-based e-discovery software company, to ... of this newly formed partnership, Cumulus Data and LDM ... Standard, downtown LA on Tuesday, May 21st. This ...
(Date:5/22/2013)... 2013 BroadConnect Telecom, the leading ... security solutions in North America announced plans to ... newest BroadConnect hosted security solutions. Available on premise, ... BroadConnect’s new Security as a Service (SaaS) enables ... connection of their choice, while optimizing internal network ...
(Date:5/22/2013)... Poor adherence to appropriate medication therapy has ... and death (some 125,000 deaths in the U.S. every ... costs. It’s been estimated that between 33% and 69% ... medication adherence — a reality that costs the American ... dire is the degree of medication non-adherence — and ...
(Date:5/22/2013)... Dallas, TX (PRWEB) May 22, 2013 Mari’s ... in Dallas, has become the first in the state of ... is called Meta Therapy- Medical and Esthetic Tissue Activation, also ... used for over four years in Europe, but has just ... Meta Therapy improves the skin from inside out by building ...
Breaking Medicine News(10 mins):Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 2Health News:LDM Global Enhances Forensic Data Collection Services with eCloudCollect 3Health News:BroadConnect Telecom to Launch Enterprise-Grade Hosted Security Solutions Engineered to Meet the Demands of Real World Business 2Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:Mari's to Offer New Treatment from Europe 2
... Government medical services in Andhra Pradesh came to ... indefinite// strike enters the second day. ,Patients ... emergency services. Patients seeking immediate medical assistance had ... prevailed at the Osmania General Hospital and the ...
... about the hearing loss caused by the MP3 players, ... paying// any heed to those warnings. But sensing the ... limiting the volume on the devices. ,The American ... to the ears associated with MP3 players. The ASHA ...
... A relatively new kind of antibiotic has been found to ... is necessary// before the drug can be prescribed, says a ... around the world, causes inflammation of the airways, or bronchi, ... thereby disrupting breathing. ,During an asthmatic attack, the ...
... Special K Snack Bites are Kellogg’s latest additions to ... on-the-go consumer//. ,The Granola Munch'ems snack bites ... and minerals such as Vitamin A, Vitamin B6, Thiamin, ... available as bite-sized-morsels in individual pouches which are available ...
... new research, men who have elevated levels of testosterone ... but may lead shorter lives// when compared with men ... ,According to foodconsumer.org, comparative studies have studied testosterone levels ... very few studies have attempted to relate testosterone to ...
... of Prestbury Avenue, Newcastle-under-Lyme, Staffs, was found not guilty of ... the manslaughter of a baby who died of head injuries ... Crown Court took five hours to reach their verdict. Passing ... the family. ,Dr El-Khadem an Egyptian by birth ...
Cached Medicine News:Health News:Doctors Strike In Andhra Enters The Second Day 2Health News:Sensing The Health Hazard MP3 Makers Tone Down The Volume 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: